These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 8387717)
21. Vaccines for Older Travelers. Jilg W Interdiscip Top Gerontol Geriatr; 2020; 43():158-181. PubMed ID: 32305985 [TBL] [Abstract][Full Text] [Related]
22. Adult use of hepatitis A vaccine in developed countries. Jilg W Vaccine; 1993; 11 Suppl 1():S6-8. PubMed ID: 8383389 [TBL] [Abstract][Full Text] [Related]
23. [Immunization recommendations for travel in the Mediterranean area]. Rendi-Wagner P; Hoeller K; Kollaritsch H; Wien Klin Wochenschr; 2004 Oct; 116(19-20):652-60. PubMed ID: 15941073 [TBL] [Abstract][Full Text] [Related]
24. [Vaccinations for overseas travelers--new evidence and recommendations]. Stürchler MP; Steffen R Ther Umsch; 2001 Jun; 58(6):362-6. PubMed ID: 11441696 [TBL] [Abstract][Full Text] [Related]
25. Vaccines to prevent hepatitis B and hepatitis A virus infections. Hadler SC Infect Dis Clin North Am; 1990 Mar; 4(1):29-46. PubMed ID: 2155262 [TBL] [Abstract][Full Text] [Related]
27. Anti-HAV seroprevalence in German travellers and hepatitis A vaccination in immune subjects. Bienzle U; Bock HL; Meister W; Clemens R; Kruppenbacher JP Lancet; 1993 Apr; 341(8851):1028. PubMed ID: 8096914 [No Abstract] [Full Text] [Related]
29. Changes to country-specific hepatitis A travel vaccination recommendation for UK travellers in 2017-responding to a vaccine shortage in the national context. Petersen J; Freedman J; Ford L; Gawthrop M; Simons H; Edelstein M; Plunkett J; Balogun K; Mandal S; Patel D Public Health; 2019 Mar; 168():150-156. PubMed ID: 30442468 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of hepatitis A prevention in travellers. Tormans G; Van Damme P; Van Doorslaer E Vaccine; 1992; 10 Suppl 1():S88-92. PubMed ID: 1335668 [TBL] [Abstract][Full Text] [Related]
31. A review of combined hepatitis A and hepatitis B vaccination for travelers. Spira AM Clin Ther; 2003 Sep; 25(9):2337-51. PubMed ID: 14604737 [TBL] [Abstract][Full Text] [Related]
32. The value of immunization against hepatitis A. Lemon SM; Shapiro CN Infect Agents Dis; 1994 Feb; 3(1):38-49. PubMed ID: 7952926 [TBL] [Abstract][Full Text] [Related]
33. Hepatitis in the tropics. Gust ID; Ruff TA Med J Aust; 1993 Nov; 159(10):691-5. PubMed ID: 8232013 [TBL] [Abstract][Full Text] [Related]
34. [Who in The Netherlands is eligible for immunization with inactivated hepatitis A vaccine?]. Leentvaar-Kuijpers A Ned Tijdschr Geneeskd; 1994 May; 138(19):941-2. PubMed ID: 8196784 [No Abstract] [Full Text] [Related]
35. Statement on hepatitis vaccines for travellers. An Advisory Committee Statement (ACS). Committee to Advise on Tropical Medicine and Travel (CATMAT) Can Commun Dis Rep; 2008 Jul; 34(ACS-2):1-24. PubMed ID: 18802989 [No Abstract] [Full Text] [Related]
36. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination. Schwartz E; Raveh D Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704 [TBL] [Abstract][Full Text] [Related]
37. New combined hepatitis A and B vaccine. Risks Of viral hepatitis related to travel. Zuckerman JN BMJ; 1998 Apr; 316(7140):1317. PubMed ID: 9554910 [No Abstract] [Full Text] [Related]
38. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: review and consensus statement on hepatitis A and B vaccination. Nothdurft HD; Dahlgren AL; Gallagher EA; Kollaritsch H; Overbosch D; Rummukainen ML; Rendi-Wagner P; Steffen R; Van Damme P; J Travel Med; 2007; 14(3):181-7. PubMed ID: 17437475 [No Abstract] [Full Text] [Related]
39. Prospects for vaccination against hepatitis A and B in Catalonia (Spain). Salleras L; Bruguera M; Buti M; DomÃngez A Vaccine; 2000 Feb; 18 Suppl 1():S80-2. PubMed ID: 10683557 [TBL] [Abstract][Full Text] [Related]
40. Vaccination against hepatitis A for travellers. All relevant costs and consequences should be measured. Hardie R BMJ; 1995 Jan; 310(6971):61-2. PubMed ID: 7827577 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]